Abstract
Obesity is a metabolic disease characterized by a chronic subclinical inflammatory response associated with an imbalance/dysregulation of cellular homeostasis in response to excessive nutrient intake and accumulation. CD4+ T-lymphocytes form different populations, Th1, Th2, Th9, Th17, Th22, and Treg cells, which have phenotypic and functional differences. Despite the active study of Th17 cells in severe disorders, their role in metabolic disorders, particularly in obesity, is not well understood. Th17 lymphocytes, depending on the microenvironment, can form pathogenic and nonpathogenic subpopulations. Systemic inflammation induces the reprogramming of the transcriptome of normal Th17 cells formed in epithelial tissues, which acquire new properties. A zone of overlapping states exists between IL-17A-producing cells, which does not allow a clear boundary between non-pathogenic Th17 and pathogenic Th17 lymphocytes. We assume that in obesity, the pool of inflammatory pathogenic Th17 cells with cytotoxic potential is a fraction of terminally differentiated memory lymphocytes which is responsible for developing autoimmune reactions.
Keywords: Obesity, type 2 diabetes mellitus, non-pathogenic Th17 cells, pathogenic Th17 cells, plasticity, CD4+CD28null cells, inflammation, autoimmune disorder.
Animated Abstract
Current Pharmaceutical Design
Title:The Pathogenic Subpopulation of Th17 Cells in Obesity
Volume: 27 Issue: 37
Author(s): Natalia Todosenko, Maria Vulf*, Kristina Yurova, Daria Skuratovskaia, Olga Khaziakhmatova, Natalia Gazatova, Olga Melashchenko, Olga Urazova and Larisa Litvinova
Affiliation:
- Center for Immunology and Cellular Biotechnology, Immanuel Kant Baltic Federal University, Kaliningrad,Russian Federation
Keywords: Obesity, type 2 diabetes mellitus, non-pathogenic Th17 cells, pathogenic Th17 cells, plasticity, CD4+CD28null cells, inflammation, autoimmune disorder.
Abstract: Obesity is a metabolic disease characterized by a chronic subclinical inflammatory response associated with an imbalance/dysregulation of cellular homeostasis in response to excessive nutrient intake and accumulation. CD4+ T-lymphocytes form different populations, Th1, Th2, Th9, Th17, Th22, and Treg cells, which have phenotypic and functional differences. Despite the active study of Th17 cells in severe disorders, their role in metabolic disorders, particularly in obesity, is not well understood. Th17 lymphocytes, depending on the microenvironment, can form pathogenic and nonpathogenic subpopulations. Systemic inflammation induces the reprogramming of the transcriptome of normal Th17 cells formed in epithelial tissues, which acquire new properties. A zone of overlapping states exists between IL-17A-producing cells, which does not allow a clear boundary between non-pathogenic Th17 and pathogenic Th17 lymphocytes. We assume that in obesity, the pool of inflammatory pathogenic Th17 cells with cytotoxic potential is a fraction of terminally differentiated memory lymphocytes which is responsible for developing autoimmune reactions.
Export Options
About this article
Cite this article as:
Todosenko Natalia , Vulf Maria *, Yurova Kristina, Skuratovskaia Daria , Khaziakhmatova Olga , Gazatova Natalia , Melashchenko Olga , Urazova Olga and Litvinova Larisa, The Pathogenic Subpopulation of Th17 Cells in Obesity, Current Pharmaceutical Design 2021; 27(37) . https://dx.doi.org/10.2174/1381612826666210101154913
DOI https://dx.doi.org/10.2174/1381612826666210101154913 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Genetic Polymorphisms of Type-1 and Type-2 Inflammatory Cytokines in Ischaemic Stroke
Vascular Disease Prevention (Discontinued) Primary and Secondary Stroke Prevention with Antiplatelet Drugs
Current Pharmaceutical Design Microalgal Fatty Acids and Their Implication in Health and Disease
Mini-Reviews in Medicinal Chemistry Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Role of the Renin-Angiotensin-Aldosterone System in the Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy Monocytes, Macrophages and Other Inflammatory Mediators of Abdominal Aortic Aneurysm
Current Pharmaceutical Design SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease
Current Drug Targets Beta-Blockers and Nitrates: Pharmacotherapy and Indications
Cardiovascular & Hematological Agents in Medicinal Chemistry Subject Index to Volume 3
Current Drug Targets - Cardiovascular & Hematological Disorders Heat Shock Protein 70 kDa as a Target for Diagnostics and Therapy of Cardiovascular and Cerebrovascular Diseases
Current Pharmaceutical Design Polyphenols of Carménère Grapes
Mini-Reviews in Organic Chemistry Role of Iron Deficiency and Overload in the Pathogenesis of Diabetes and Diabetic Complications
Current Medicinal Chemistry The Vasoactive Role of Nitric Oxide: Physiological and Morphological Aspects
Current Pharmaceutical Biotechnology Circulating Biomarkers for the Diagnosis and Prognosis of Heart Failure
Current Medicinal Chemistry Interleukin-10: An Anti-Inflammatory and Immunosuppressive Cytokine in the Normal and Pathological Immune Response
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Applications of Artificial Neural Networks in Medical Science
Current Clinical Pharmacology Acute Kidney Injury: Turning the Tide
Current Drug Targets A Novel Systemic Indicator of Periodontal Tissue Damage: Ischemia Modified Albumin
Combinatorial Chemistry & High Throughput Screening Paclitaxel Formulations: Challenges and Novel Delivery Options
Current Drug Delivery